University of Ioannina
Η προγνωστική σημασία των δεικτών: ειδικό προστατικό αντιγόνο (PSA), μεταλλαγμένη πρωτεϊνη p53, οιστρογονικοί υποδοχείς (ER) και προγεστερονικοί υποδοχείς (PgR) στον καρκίνο του μαστού (κλινικοεργαστηριακή μελέτη)
Abstract
dc:descriptionTHERE IS NO, AS YET, A SINGLE TUMOR INDEX SUFFICIENTLY SPECIFIC TO PREDICT WITH ACCURACY THE OUTCOME FOR EACH BREAST CANCER PATIENT. IN RECENT YEARS, PROGRESS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY HAD ALLOWED THE DETERMINATION OF VARIOUS PROTEINS WHO WERE STUDIED FOR THEIR PROGNOSTIC SIGNIFICANCE IN BREAST CANCER PATIENTS. PROSTATE SPECIFIC ANTIGEN (PSA) WHICH WAS THOUGHT TO BE EXCRETED ONLY BY THE EPITHELIAL CELLS OF PROSTATE, HAS ALSO BEEN RECENTLY DETERMINED IN BREAST TUMORS. ALSO, THE PRESENT OF MUTANT P53 PROTEIN IN BREAST TUMORS SUGGEST AN UNFAVORABLE PROGNOSTIC MARKER FOR BREAST CANCER PATIENTS. TO ESTIMATE THE PROGNOSTIC SIGNIFICANCE OF PSA AND P53 EXPRESSION IN BREAST TUMOR CYTOSOL, WE RETROSPECTIVELY STUDIED 219 CANCER PATIENTS (27 PRE- AND 192 POSTMENOPAUSAL) WHO WERE SURGICALLY TREATED IN OUR INSTITUTE FROM OCT. 1992 TOSEPT. 1995. PSA AND P53 IMMUNOREACTIVITY WAS DETERMINED WITH ULTRASENSITIVE TIME-RESOLVED IMMUNOFLUOROMETRIC ASSAY. PATIENTS WERE DEFINED AS PSA POSITIVEAND PSA NEGATIVE ACCORDING TO A CUT-OFF POINT OF 1 PR/MG. IN PREMENOPAUSAL CANCER PATIENTS, 15 WERE PSA POSITIVE, WHILST, 131 POSTMENOPAUSAL PATIENTS WERE PSA POSITIVE. ACCORDING TO A CUT-OFF POINT OF 0,4 ΜG/G FOR P53 EXPRESSION 14 PREMENOPAUSAL AND 37 POSTMENOPAUSAL CANCER PATIENTS WERE P53+. WE CLASSIFIED THE PATIENTS IN THE SUBGROUPS OF PSA+ AND PSA-, P53+ AND P53- AND ALSO PSA+/P53- AND PSA- /P53+ AND WE SEARCH FOR THEIR RELATIONSHIP TO OTHER PROGNOSTIC INDICES, TO CANCER RELAPSE AND DESEASE FREE INTERVAL. (ABSTRACT TRUNCATED)
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 1999
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Griniatsos, John
- Γκρινιάτσος, Ιωάννης
Subjects
dc:subject × 16- Ειδικό προστατικό αντιγόνο
- Καρκίνος
- Καρκίνος μαστού
- Μεσοδιάστημα ελεύθερο νόσου
- p53, Μεταλλαγμένη πρωτεϊνη
- Ορμονικοί υποδοχείς
- Breast cancer
- Cancer
- Disease free interval
- Hormonal receptors
- Mutant protein p53
- Prostatic specific antigen (PSA)
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/11320